Retroviral vector-mediated gene therapy is promising, but genotoxicity has limited its use in the clinic. Genotoxicity is highly dependent on the retroviral vector used, and foamy viral (FV) vectors appear relatively safe. However, internal promoters may still potentially activate nearby genes. We developed insulated FV vectors, using four previously described insulators: a version of the well-studied chicken hypersensitivity site 4 insulator (650cHS4), two synthetic CCCTC-binding factor (CTCF)-based insulators, and an insulator based on the CCAAT box-binding transcription factor/nuclear factor I (7xCTF/NF1). We directly compared these insulators for enhancer-blocking activity, effect on FV vector titer, and fidelity of transfer to both proviral long terminal repeats. The synthetic CTCF-based insulators had the strongest insulating activity, but reduced titers significantly. The 7xCTF/NF1 insulator did not reduce titers but had weak insulating activity. The 650cHS4-insulated FV vector was identified as the overall most promising vector. Uninsulated and 650cHS4-insulated FV vectors were both significantly less genotoxic than gammaretroviral vectors. Integration sites were evaluated in cord blood CD34+ cells and the 650cHS4-insulated FV vector had fewer hotspots compared with an uninsulated FV vector. These data suggest that insulated FV vectors are promising for hematopoietic stem cell gene therapy.
Get full access to this article
View all access options for this article.
References
1.
BordignonC, NotarangeloLD, NobiliN, et al.Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science, 1995; 270:470–475.
2.
Hacein-Bey-AbinaS, Le DeistF, CarlierF, et al.Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med, 2002; 346:1185–1193.
3.
WangGP, BerryCC, MalaniN, et al.Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood, 2010; 115:4356–4366.
4.
Cavazzana-CalvoM, PayenE, NegreO, et al.Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 2010; 467:318–322.
5.
SantilliG, AlmarzaE, BrendelC, et al.Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther, 2011; 19:122–132.
6.
AiutiA, BiascoL, ScaramuzzaS, et al.Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 2013; 341:1233151.
7.
Hacein-Bey-AbinaS, von KalleC, SchmidtM, et al.A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003; 348:255–256.
8.
Hacein-Bey-AbinaS, GarrigueA, WangGP, et al.Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 2008; 118:3132–3142.
9.
LiZ, DullmannJ, SchiedlmeierB, et al.Murine leukemia induced by retroviral gene marking. Science, 2002; 296:497.
10.
BraunCJ, BoztugK, ParuzynskiA, et al.Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med, 2014; 6:227–233.
11.
HoweSJ, MansourMR, SchwarzwaelderK, et al.Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis after gene therapy of SCID-X1 patients. J Clin Invest, 2008; 118:3143–3150.
12.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 12:401–409.
13.
ZychlinskiD, SchambachA, ModlichU, et al.Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther, 2008; 16:718–725.
14.
BokhovenM, StephenSL, KnightS, et al.Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol, 2009; 83:283–294.
15.
BosticardoM, GhoshA, DuY, et al.Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol Ther, 2009; 17:1910–1918.
LiCL, XiongD, StamatoyannopoulosG, et al.Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther, 2009; 17:716–724.
19.
CociEG, MaetzigT, ZychlinskiD, et al.Novel self-inactivating vectors for reconstitution of Wiskott-Aldrich syndrome. Curr Gene Ther, 2015; 15:245–254.
20.
TrobridgeGD, MillerDG, JacobsMA, et al.Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A, 2006; 103:1498–1503.
21.
NowrouziA, DittrichM, KlankeC, et al.Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol, 2006; 87:1339–1347.
22.
DeyleDR, KhanIF, RenG, et al.Lack of genotoxicity due to foamy virus vector integration in human iPSCs. Gene Ther, 2013; 20:868–873.
23.
JosephsonNC, VassilopoulosG, TrobridgeGD, et al.Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci U S A, 2002; 99:8295–8300.
24.
NasimuzzamanM, KimYS, WangYD, et al.High-titer foamy virus vector transduction and integration sites of human CD34+ cell-derived SCID-repopulating cells. Mol Ther Methods Clin Dev, 2014; 1:14020.
25.
HendriePC, HuoY, StolitenkoRB, et al.A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Ther, 2008; 16:534–540.
26.
TrobridgeG, and RussellDW. Cell cycle requirements for transduction by foamy virus vectors compared with those of oncovirus and lentivirus vectors. J Virol, 2004; 78:2327–2335.
27.
EmeryDW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther, 2011; 22:761–774.
28.
ArumugamPI, HigashimotoT, UrbinatiF, et al.Genotoxic potential of lineage-specific lentivirus vectors carrying the β-globin locus control region. Mol Ther, 2009; 17:1929–1937.
29.
NeffT, ShotkoskiF, and StamatoyannopoulosG. Stem cell gene therapy, position effects and chromatin insulators. Stem Cells, 1997; 15(Suppl 1):265–271.
30.
WestAG, GasznerM, and FelsenfeldG. Insulators: many functions, many mechanisms. Genes Dev, 2002; 16:271–288.
31.
Burgess-BeusseB, FarrellC, GasznerM, et al.The insulation of genes from external enhancers and silencing chromatin. Proc Natl Acad Sci U S A, 2002; 99:16433–16437.
32.
WallaceJA, and FelsenfeldG. We gather together: insulators and genome organization. Curr Opin Genet Dev, 2007; 17:400–407.
33.
ArumugamPI, UrbinatiF, VeluCS, et al.The 3′ region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One, 2009; 4:e6995.
34.
GaussinA, ModlichU, BaucheC, et al.CTF/NF1 transcription factors act as potent genetic insulators for integrating gene transfer vectors. Gene Ther, 2012; 19:15–24.
35.
ChungJH, WhiteleyM, and FelsenfeldG. A 5′ element of the chicken β-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell, 1993; 74:505–514.
36.
ChungJH, BellAC, and FelsenfeldG. Characterization of the chicken β-globin insulator. Proc Natl Acad Sci U S A, 1997; 94:575–580.
37.
PankiewiczR, KarlenY, ImhofMO, et al.Reversal of the silencing of tetracycline-controlled genes requires the coordinate action of distinctly acting transcription factors. J Gene Med, 2005; 7:117–132.
38.
FerrariS, SimmenKC, DusserreY, et al.Chromatin domain boundaries delimited by a histone-binding protein in yeast. J Biol Chem, 2004; 279:55520–55530.
39.
CesanaD, RanzaniM, VolpinM, et al.Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther, 2014; 22:774–785.
40.
TrobridgeGD, BeardBC, WuRA, et al.Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One, 2012; 7:e45173.
41.
OlszkoME, AdairJE, LindeI, et al.Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Ther, 2015; 22:591–595.
42.
TrobridgeGD, WuRA, HansenM, et al.Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther, 2010; 18:725–733.
43.
KiemHP, WuRA, SunG, et al.Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther, 2010; 17:37–49.
44.
ZhaoC, TengEM, SummersRGJr, et al.Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci, 2006; 26:3–11.
45.
BeardBC, AdairJE, TrobridgeGD, et al.High-throughput genomic mapping of vector integration sites in gene therapy studies. Methods Mol Biol, 2014; 1185:321–344.
46.
RaeDT, CollinsCP, HocumJD, et al.Modified genomic sequencing PCR using the MiSeq platform to identify retroviral integration sites. Hum Gene Ther Methods, 2015:26:221–227.
47.
ZhangJ, KobertK, FlouriT, et al.PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics, 2014; 30:614–620.
48.
LanderES, LintonLM, BirrenB, et al.Initial sequencing and analysis of the human genome. Nature, 2001; 409:860–921.
49.
HocumJD, BattrellLR, MaynardR, et al.VISA—Vector integration site analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing. BMC Bioinformatics, 2015; 16:212.
50.
UrbinatiF, ArumugamP, HigashimotoT, et al.Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3′LTR. Mol Ther, 2009; 17:1527–1536.
51.
RamezaniA, HawleyTS, and HawleyRG. Combinatorial incorporation of enhancer-blocking components of the chicken β-globin 5′HS4 and human T-cell receptor α/δ BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells, 2008; 26:3257–3266.
52.
KimTH, AbdullaevZK, SmithAD, et al.Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell, 2007; 128:1231–1245.
53.
HanawaH, YamamotoM, ZhaoH, et al.Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken β-globin locus HS4 insulator element. Mol Ther, 2009; 17:667–674.
54.
EmeryDW, YannakiE, TubbJ, et al.A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A, 2000; 97:9150–9155.
55.
AnW, and TelesnitskyA. Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. Virology, 2001; 286:475–482.
56.
NielsenTT, JakobssonJ, RosenqvistN, et al.Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants. BMC Biotechnology, 2009; 9:13.
57.
BredaL, CasuC, GardenghiS, et al.Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. PLoS One, 2012; 7:e32345.
58.
FitzGeraldTJ, HenaultS, SakakeenyM, et al.Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate. Radiation Res, 1990; 122:44–52.
59.
ModlichU, NavarroS, ZychlinskiD, et al.Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther, 2009; 17:1919–1928.
60.
CattoglioC, FacchiniG, SartoriD, et al.Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood, 2007; 110:1770–1778.
61.
SuzukiT, ShenH, AkagiK, et al.New genes involved in cancer identified by retroviral tagging. Nat Genet, 2002; 32:166–174.
62.
LiuM, MauranoMT, WangH, et al.Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol, 2015; 33:198–203.
63.
NakahashiH, KwonKR, ReschW, et al.A genome-wide map of CTCF multivalency redefines the CTCF code. Cell Rep, 2013; 3:1678–1689.
64.
RheeHS, and PughBF. Comprehensive genome-wide protein–DNA interactions detected at single-nucleotide resolution. Cell, 2011; 147:1408–1419.
65.
ChenH, TianY, ShuW, et al.Comprehensive identification and annotation of cell type-specific and ubiquitous CTCF-binding sites in the human genome. PLoS One, 2012; 7:e41374.
66.
KiemHP, AllenJ, TrobridgeG, et al.Foamy-virus-mediated gene transfer to canine repopulating cells. Blood, 2007; 109:65–70.
67.
MalikP, and ArumugamPI. Gene therapy for β-thalassemia. Hematology Am Soc Hematol Educ Program, 2005:45–50.
68.
HunterMJ, ZhaoH, TuschongLM, et al.Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters. Hum Gene Ther, 2011; 22:689–696.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
